度洛西汀与艾司西酞普兰对伴躯体化症状抑郁症的疗效比较

目的:比较度洛西汀与艾司西酞普兰对急性期伴躯体化症状抑郁症的疗效及安全性。方法:70例门诊和住院患者,随机分为度洛西汀治疗35例为研究组,艾司西酞普兰治疗35例为对照组,疗程8周。采用17项汉密尔顿抑郁量表(HAMD17)和汉密尔顿焦虑量表(HAMA)评价症状严重程度,药物不良反应评价用TESS。结果:两组患者治疗后HAMD和HAMA评分较治疗前均有显著性降低(P<0.01);第8周研究组患者与对照组有效率分别为78.79%、53.13%,两组患者疗效差异有统计学意义(P<0.05)。两组患者与药物有关的不良反应出现频率的差异无统计学意义(P>0.05)。结论:与艾司西酞普兰比较,度洛西汀治疗伴躯体化症状的抑郁症疗效更为确切,起效较快,安全性较高。

Comparative study of duloxetine and escitalopram intreatment of depression with somatization symptoms

Objective：To compare effectiveness and safety of duloxetine and escitalopram in treatment of depression withsoma-tization symptoms. Methods：A total of 70 outpatients and inpatients with depression were randomly divided into duloxetine （ 35 pa-tients）group and escitalopram（35 patients）group. The duration of treatment was 8 weeks. Severity was assessed by 17-item Hamilton depression scale （HAMD）17 and Hamilton anxiety scale（HAMA）. The safety was evaluated with treatment emergent symptom scale （ TESS） . Results：The HAMD and HAMA scores after the treatment of the two groups were significantly lower than those before the treatment （P〈0. 01）. At the 8th weeks, the effective rates of research group and control group were 78. 79% and 53. 13%, and the difference was statistically significant （P〈0. 05）. Therewere no significant statistical differences in the adverse event frequencies be-tween the two groups （P〉0. 05）. Conclusions：Duloxetine would have better efficacy and higher safety, and takes effects more rapidly in the treatment of depression with somatization symptoms, compared with escitalopram.